News articles about Celgene (NASDAQ:CELG) have trended somewhat positive recently, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Celgene earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.1964377319196 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the media headlines that may have effected Accern Sentiment’s scoring:

Celgene (CELG) traded up $0.93 during trading hours on Friday, reaching $102.65. 8,098,686 shares of the company were exchanged, compared to its average volume of 6,610,000. Celgene has a 52 week low of $94.55 and a 52 week high of $147.17. The stock has a market capitalization of $80,820.00, a price-to-earnings ratio of 24.21, a PEG ratio of 0.65 and a beta of 1.77. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The company had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same period in the prior year, the firm earned $1.58 earnings per share. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. sell-side analysts predict that Celgene will post 6.7 EPS for the current fiscal year.

A number of research analysts have recently commented on the stock. Royal Bank of Canada restated a “buy” rating and issued a $173.00 price target on shares of Celgene in a report on Thursday, October 5th. Morgan Stanley cut shares of Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price target on the stock. in a report on Thursday, October 5th. Robert W. Baird restated a “buy” rating and issued a $162.00 price target on shares of Celgene in a report on Thursday, September 21st. Cantor Fitzgerald restated a “buy” rating and issued a $162.00 price target on shares of Celgene in a report on Tuesday, September 26th. Finally, Vetr upgraded shares of Celgene from a “hold” rating to a “buy” rating and set a $146.58 price target on the stock in a report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $129.98.

COPYRIGHT VIOLATION NOTICE: “Celgene (CELG) Given Coverage Optimism Rating of 0.12” was posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2018/01/19/celgene-celg-given-coverage-optimism-rating-of-0-12.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Insider Buying and Selling by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.